Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.
Camilleri M, Lembo AJ, Lavins BJ, MacDougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.